CD79A and COVID-19: Anti-β2GPI binds to multiple receptors on the surface of platelets, leading to the activation of platelets and endothelium.[8] It also activates the complement pathway which is significantly correlated with the coagulation pathways.[9] IgA anti-β2GPI associated with thrombotic events[10] are the most commonly observed aPL in patients with COVID-19 and were present in 28.8% (19 of 66) of critically ill patients.[11] Before treatment, the patient in our case presented with low positivity for IgG in the aCL and LA assays.